Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

You may also be interested in...



Indian Companies Ramping Up For Follow-On Biologics

Like Western companies, Indian drug makers are buying or forming alliances with biotechs to enrich their pipelines but with the added goal of ramping up to do what they currently do best: create generic versions of branded drugs

Indian Companies Ramping Up For Follow-On Biologics

Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY

Indian Companies Ramping Up For Follow-On Biologics

Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel